JP2006505616A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006505616A5 JP2006505616A5 JP2004551909A JP2004551909A JP2006505616A5 JP 2006505616 A5 JP2006505616 A5 JP 2006505616A5 JP 2004551909 A JP2004551909 A JP 2004551909A JP 2004551909 A JP2004551909 A JP 2004551909A JP 2006505616 A5 JP2006505616 A5 JP 2006505616A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- hydrogen
- complex
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 15
- 150000004696 coordination complex Chemical class 0.000 claims description 14
- 229910021645 metal ion Inorganic materials 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 4
- 210000005013 brain tissue Anatomy 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 53
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000003342 alkenyl group Chemical group 0.000 claims 14
- 125000000304 alkynyl group Chemical group 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 6
- 229910052702 rhenium Inorganic materials 0.000 claims 6
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 5
- 229910052713 technetium Inorganic materials 0.000 claims 5
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 229910052797 bismuth Inorganic materials 0.000 claims 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 229910052802 copper Inorganic materials 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- 229910052733 gallium Inorganic materials 0.000 claims 2
- 229910052738 indium Inorganic materials 0.000 claims 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 229910052703 rhodium Inorganic materials 0.000 claims 2
- 239000010948 rhodium Substances 0.000 claims 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims 2
- 229910052727 yttrium Inorganic materials 0.000 claims 2
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 229940056501 technetium 99m Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000000056 organ Anatomy 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42498002P | 2002-11-08 | 2002-11-08 | |
| US60/424,980 | 2002-11-08 | ||
| PCT/US2003/035618 WO2004043380A2 (en) | 2002-11-08 | 2003-11-08 | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006505616A JP2006505616A (ja) | 2006-02-16 |
| JP2006505616A5 true JP2006505616A5 (enExample) | 2010-05-13 |
| JP4796301B2 JP4796301B2 (ja) | 2011-10-19 |
Family
ID=32312909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004551909A Expired - Fee Related JP4796301B2 (ja) | 2002-11-08 | 2003-11-08 | テクネチウム−９９ｍ及びレニウムで標識した小型作用剤及び組織、臓器及び腫瘍の画像化方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060159617A1 (enExample) |
| EP (1) | EP1567495A4 (enExample) |
| JP (1) | JP4796301B2 (enExample) |
| AU (1) | AU2003290673B2 (enExample) |
| CA (1) | CA2505529C (enExample) |
| WO (1) | WO2004043380A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| EP2043655A2 (en) | 2006-04-25 | 2009-04-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| JP4705695B2 (ja) | 2007-10-11 | 2011-06-22 | アストラゼネカ アクチボラグ | プロテインキナーゼｂ阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体 |
| WO2010144891A1 (en) * | 2009-06-13 | 2010-12-16 | President And Fellows Of Harvard College | Compositions and methods for imaging tissues, organs and tumors |
| JP5894540B2 (ja) | 2010-02-18 | 2016-03-30 | ブイティーブイ・セラピューティクス・エルエルシー | フェニル−ヘテロアリール誘導体とその使用の方法 |
| JP6080837B2 (ja) | 2011-04-01 | 2017-02-15 | アストラゼネカ アクチボラグ | 療法的治療 |
| CN102219818B (zh) * | 2011-05-05 | 2014-01-08 | 江苏省原子医学研究所 | 胸苷衍生物及其制备方法和其作为配体在制备肿瘤显像剂中的应用 |
| KR102035361B1 (ko) | 2011-11-30 | 2019-11-08 | 아스트라제네카 아베 | 암의 병용 치료 |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| WO2015200187A1 (en) * | 2014-06-27 | 2015-12-30 | Reiley Pharmaceuticals, Inc. | Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4638051A (en) * | 1984-04-30 | 1987-01-20 | The Johns Hopkins University | Brain imaging radiopharmaceuticals |
| ZA852981B (en) * | 1984-04-30 | 1985-11-27 | Univ Johns Hopkins | Brain imaging radiopharmaceuticals |
| US6241963B1 (en) * | 1995-10-19 | 2001-06-05 | The Trustees Of The University Of Pennsylvania | Dopamine and serotonin transporter ligands and imaging agents |
| US6171576B1 (en) * | 1995-11-03 | 2001-01-09 | Organix Inc. | Dopamine transporter imaging agent |
| US5919934A (en) * | 1997-02-19 | 1999-07-06 | The George Washington University | Compounds, compositions, and methods for cancer imaging and therapy |
| CA2285516C (en) * | 1999-05-12 | 2010-12-07 | President And Fellows Of Harvard College | Dopamine transporter imaging agents |
| US6515131B2 (en) * | 2000-02-22 | 2003-02-04 | Biostream Therapeutics, Inc. | Imagining agents for diagnosis of Parkinson's disease |
| AU6968301A (en) * | 2000-04-28 | 2001-11-12 | Harvard College | Small technetium-99m and rhenium labeled agents and methods for imaging tumors |
-
2003
- 2003-11-08 WO PCT/US2003/035618 patent/WO2004043380A2/en not_active Ceased
- 2003-11-08 AU AU2003290673A patent/AU2003290673B2/en not_active Ceased
- 2003-11-08 EP EP03783254A patent/EP1567495A4/en not_active Withdrawn
- 2003-11-08 US US10/534,225 patent/US20060159617A1/en not_active Abandoned
- 2003-11-08 CA CA2505529A patent/CA2505529C/en not_active Expired - Fee Related
- 2003-11-08 JP JP2004551909A patent/JP4796301B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5946992B2 (ja) | 灌流造影を含む適用のための造影剤 | |
| Zhang et al. | Comparative study of subcutaneous and orthotopic mouse models of prostate cancer: vascular perfusion, vasculature density, hypoxic burden and BB2r-targeting efficacy | |
| ligan et al. | 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals | |
| JP2006505616A5 (enExample) | ||
| DE69819478T2 (de) | Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore | |
| Bailly et al. | Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma | |
| Shukla et al. | Dimercaptosuccinic acid: A multifunctional cost effective agent for imaging and therapy | |
| CN113105461A (zh) | 七甲基碳菁染料-交联四环胺螯合剂偶联物、复合物及其用途 | |
| Fang et al. | A novel 18F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice | |
| JP2004501093A5 (enExample) | ||
| CA2407592A1 (en) | Small technetium-99m and rhenium labeled agents and methods for imaging tumors | |
| Alirezapour et al. | Optimized preparation and preliminary evaluation of [64Cu]–DOTA–trastuzumab for targeting ErbB2/Neu expression | |
| WO2004043380A3 (en) | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors | |
| EP2711026A1 (en) | Radioactive fluorine-labeled quinoxaline compound | |
| US5914096A (en) | Arsenic-72 labeled compounds for tissue specific medical imaging | |
| JP5604680B2 (ja) | 放射性標識薬剤 | |
| EP3177598A1 (en) | Macrocyclic complexes, their process of preparation and use as pet imaging agents | |
| JP7608378B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 | |
| Fan et al. | Development of a CD9-Targeted Radiopharmaceutical for Imaging and Radionuclide Therapy in CD9-Positive Glioma | |
| KR20250004887A (ko) | 영상화 및 요법 적용을 위한 ntsr 표적화 제제의 개발 | |
| Pang et al. | Using 18 F-ML-10 PET/CT imaging to detect atherosclerosis lesions and apoptotic processes in mice. | |
| KR20210052435A (ko) | 방사성 이미다조티아디아졸 유도체 화합물 | |
| Iyer et al. | Novel Human Single Chain Antibody Fragments That Are Rapidly Internalizing Effectively Target Epithelioid and... | |
| Bailly et al. | Comparison of Immuno-PET of CD138 and PET imaging with | |
| Dore | SPECT/CT in the neuroendocrine tumours (NET) assessment by means of 111InOctreotide somatostatin receptors scintigraphy (SRS). |